Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

About this update from Aspire Biopharma Holdings, Inc.

[{"type":"text","content":"Prioritizes High-Value Approved Drugs in Multi-Billion-Dollar Markets to Accelerate Commercialization","length":101,"tagName":"p"},{"type":"text","content":"Future Platform Expansion into CNS, Men's Health, and Anti-Nausea","length":69,"tagName":"p"},{"type":"text","content":"ESTERO, FL / ACCESS Newswire / October 1, 2025 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), developer of a multi-faceted patent-pending sublingual drug delivery technology, today announced pipeline progress and key milestones expected through the remainder of 2025 and early 2026. The company is focusing its pipeline on reformulating approved drugs for multi-billion-dollar markets by utilizing its disruptive, patent-pending sublingual delivery technology.","length":510,"tagName":"p"},{"type":"text","content":"Anticipated Upcoming Milestones","length":31,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Sublingual High-dose Aspirin (Lead Program)","length":43,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"H2 2025: Request meeting with FDA to discuss 505(b)(2) pathway.","length":63,"tagName":"p"}]},{"val":[{"type":"text","content":"H2 2025: Target submission of New Drug Application (NDA).","length":57,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":120,"olType":false}]},{"val":[{"type":"text","content":"Sublingual ED medication","length":24,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"H1 2026: Finalize formulation and manufacture test product.","length":59,"tagName":"p"}]},{"val":[{"type":"text","content":"Mid-2026: Initiate Phase 1 pharmacokinetic (PK) clinical cross-over study.","length":74,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":133,"olType":false}]},{"val":[{"type":"text","content":"Sublingual Semaglutide","length":22,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"H1 2026: Finalize formulation and manufacture test product.","length":59,"tagName":"p"}]},{"val":[{"type":"text","content":"H1 2026 Initial Phase 1 pharmacokinetic clinical cross-over study.","length":66,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":125,"olType":false}]}],"tagName":"ul","bulletedList":true,"length":467,"olType":false},{"type":"text","content":""Our pipeline is focused...

More updates from Aspire Biopharma Holdings, Inc.